Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Neurogene Inc.

< Previous 1 2 Next >
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Inc. Announces Pricing of $125 Million Public Offering
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Inc. Announces Proposed Public Offering
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Tickers NGNE
News headline image
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.